You are here: Welcome to the MPKB » Welcome to the MPKB » Resources for patients » Length of the Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:patients:mp_duration [10.21.2016] – [Length of the Marshall Protocol] remain on OLM replaces 'the MP' sallieqhome:patients:mp_duration [07.03.2017] – [Factors influencing length of treatment] sallieq
Line 3: Line 3:
 <relatedarticle> [[home:alternate:spontaneous_remission|Spontaneous remission is a myth]]</article> <relatedarticle> [[home:alternate:spontaneous_remission|Spontaneous remission is a myth]]</article>
  
-The exact duration of the Marshall Protocol (MP) depends on any number of factors, including degree of illness, amount of fibrosis, subclinical inflammation, the health of the kidneys, and personal preference to remain on Olmesartan.+The exact duration of the Marshall Protocol (MP) depends on any number of factors, including degree of illness, amount of fibrosis, ability of the kidneys to process and expel breakdown material, subclinical inflammation, exposure to unavoidable immune suppressants, and personal preference to remain on Olmesartan.
  
 While someone who is very ill might expect the MP to take five or more years, there is no way to know for sure how long the treatment will take. Due to the nature of immunopathology, feelings of well-being and blood markers of disease tend to be variable in the short-term and improve over the long-term. Also owing to the nature of infection, different symptoms will improve at different rates. While someone who is very ill might expect the MP to take five or more years, there is no way to know for sure how long the treatment will take. Due to the nature of immunopathology, feelings of well-being and blood markers of disease tend to be variable in the short-term and improve over the long-term. Also owing to the nature of infection, different symptoms will improve at different rates.
Line 29: Line 29:
   * **Prior use of immunosuppressants and immunomodulatory medications** –   * **Prior use of immunosuppressants and immunomodulatory medications** –
   * **Fibrosis** – When the immune system fails to kill a pathogen, it encases the diseased tissue in collagen. This process is known as fibrosis. MP patients with fibrosis can expect to be killing pockets of these for a long time, extending the length of the treatment, as the fibrosis remodels.   * **Fibrosis** – When the immune system fails to kill a pathogen, it encases the diseased tissue in collagen. This process is known as fibrosis. MP patients with fibrosis can expect to be killing pockets of these for a long time, extending the length of the treatment, as the fibrosis remodels.
-  * **Excessive exposure to wireless technologies** There is now a growing body of evidence pointing to emf exposure as an immune suppressant impacting pregnancy, childhood and those with immune related disorders .+  * **Unshielded exposure to wireless technologies** There is now a growing body of evidence pointing to emf exposure as an immune suppressant impacting pregnancy, childhood and those with immune related disorders .
  
  
Line 41: Line 41:
  
 //**Greg Blaney, M.D.**//</blockquote> //**Greg Blaney, M.D.**//</blockquote>
 +
 +Some in the latter group have examined their exposure to EMF and discovered that sufficient reduction in exposure resulted in a renewed immune recovery trajectory, often differing in emphasis. 
  
  
home/patients/mp_duration.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.